Semaglutide · eligibility
Semaglutide eligibility: who it's for and who should avoid it
Labeled eligibility, contraindications, and why compounded semaglutide screening deserves extra care.
Approved semaglutide for weight management is labeled for Adults with a BMI of 30 or greater (obesity), or 27 or greater (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or dyslipidemia. There is also an adolescent (12+) indication for the approved product. Eligibility is a clinical decision made with a prescriber, who also screens for contraindications. A compounded semaglutide program may apply looser screening, which is a reason to be more careful, not less.
What sets semaglutide eligibility apart
Semaglutide's approved eligibility is unusually broad among these products. Beyond the adult weight-management indication, Wegovy carries an adolescent indication (ages 12 and older) and, following the SELECT trial, a cardiovascular risk-reduction indication in adults with established cardiovascular disease and overweight or obesity. The same molecule is also approved for type 2 diabetes (Ozempic, Rybelsus). That breadth means a prescriber may weigh cardiovascular or diabetes context, not just BMI, when considering semaglutide.
It also means compounded semaglutide eligibility claims deserve scrutiny: a program may invoke the molecule's broad approved profile while dispensing an unapproved compounded product — including, in some cases, a salt form that is not the approved active ingredient at all.
Who the approved label covers
For weight management, approved semaglutide is indicated for Adults with a BMI of 30 or greater (obesity), or 27 or greater (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or dyslipidemia. There is also an adolescent (12+) indication for the approved product. The same molecule is separately approved for type 2 diabetes. These indications reflect the populations actually studied in the STEP program.
Contraindications and cautions
| Condition | Consideration |
|---|---|
| Medullary thyroid carcinoma history | Personal or family history — contraindicated (boxed warning). |
| MEN 2 syndrome | Multiple endocrine neoplasia type 2 — contraindicated. |
| Pregnancy / planning pregnancy | Not recommended; discuss timing with a clinician. |
| History of pancreatitis | Use with caution and clinical judgment. |
| Prior serious hypersensitivity | To the molecule or excipients — contraindicated. |
Why compounded eligibility deserves extra care
A telehealth intake for a compounded product can be quick, but the underlying medical screening should not be. The contraindications above apply regardless of whether the product is approved or compounded, and a fast checkout does not remove them. Bring your full history to the clinician.
What the evidence shows
- Approved semaglutide labeling defines clear eligibility and contraindications.
What the evidence does not show
- That an online checkout equals clinical eligibility.
- That compounded programs screen identically to a full medical evaluation.
Frequently asked questions
Who is eligible for semaglutide?
Adults meeting the labeled BMI criteria (Adults with a BMI of 30 or greater (obesity), or 27 or greater (overweight) with…), decided with a prescriber who screens for contraindications.
Who should not take semaglutide?
People with a personal/family history of medullary thyroid carcinoma or MEN 2, and others per the contraindication list; discuss pregnancy and pancreatitis history with a clinician.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.